Yongjun Quan
Overview
Explore the profile of Yongjun Quan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quan Y, Wang M, Zhang H, Lu D, Ping H
iScience
. 2024 Dec;
27(12):111351.
PMID: 39650727
Prostate cancer (PCa) exhibits significant intratumor heterogeneity, frequently manifesting as a multifocal disease. This study utilized Visium spatial transcriptomics (ST) to explore transcriptome patterns in PCa regions with varying Gleason...
2.
Quan Y, Zhang H, Wang M, Ping H
Comput Struct Biotechnol J
. 2024 Sep;
23:3315-3326.
PMID: 39310280
Prostate cancer (PCa) is a multifocal disease characterized by genomic and phenotypic heterogeneity within a single gland. In this study, Visium spatial transcriptomics (ST) analysis was applied to PCa tissues...
3.
Quan Y, Zhang H, Wang M, Ping H
iScience
. 2023 Dec;
26(12):108429.
PMID: 38077153
Prostate cancer (PCa) frequently presents as a multifocal disease within a single gland. Herein, the transcriptome-wide profiles of glandular epithelial (GE) cells of four PCa tissues with various Gleason scores...
4.
Quan Y, Ping H, Wang M, Zhang X
DNA Cell Biol
. 2023 Aug;
42(9):563-577.
PMID: 37540080
N-cadherin (cadherin-2 [CDH2]) is widely known as the promoter of prostate cancer (PCa) invasion and castration resistance. However, the biological mechanism of N-cadherin in PCa progression is unclear. In this...
5.
Quan Y, Zhang X, Wang M, Ping H
Front Oncol
. 2022 Oct;
12:981226.
PMID: 36237332
Background: Epigenetic reprogramming through dysregulated histone lysine methylation (HLM) plays a crucial role in prostate cancer (PCa) progression. This study aimed to comprehensively evaluate HLM modification patterns in PCa microenvironment...
6.
Quan Y, Zhang X, Ping H
Cancer Cell Int
. 2022 Jan;
22(1):33.
PMID: 35045837
Background: Epigenetic reprogramming reportedly has a crucial role in prostate cancer (PCa) progression. RNA modification is a hot topic in epigenetics, and N6-methyladenosine (m6A) accounts for approximately 60% of RNA...
7.
Quan Y, Zhang X, Butler W, Du Z, Wang M, Liu Y, et al.
Int J Biol Sci
. 2021 Sep;
17(13):3288-3304.
PMID: 34512147
The dysregulation of androgen receptor () signaling is a critical event in the progression of prostate cancer (PCa) and hormone therapy consisting of androgen deprivation (ADT) or AR inhibition is...
8.
Quan Y, Cui Y, Wahafu W, Liu Y, Ping H, Zhang X
Am J Cancer Res
. 2020 Jun;
10(5):1608-1629.
PMID: 32509400
Prostate cancer (PCa) is one of the most prevalent malignancies in men. However, the molecular mechanism controlling the transformation of androgen-dependent PCa (ADPC) to castration-resistant PCa (CRPC) is largely unknown....
9.
Quan Y, Lei H, Wahafu W, Liu Y, Ping H, Zhang X
Biomed Pharmacother
. 2019 Oct;
120:109490.
PMID: 31574376
Background: Emerging preclinical evidence suggests a critical role for androgen-mediated androgen receptor (AR) signaling in bladder cancer progression. However, researchers have not determined whether autophagy modulates the efficacy of an...
10.
Quan Y, Jeong C, Kwak C, Kim H, Kim H, Ku J
Medicine (Baltimore)
. 2017 Oct;
96(42):e8300.
PMID: 29049231
Background: Intravesical bacillus Calmette-Guerin (BCG) instillation is widely used as an adjuvant therapy after transurethral resection of bladder tumor (TURBT) in patients with intermediate- and high-risk nonmuscle invasive bladder cancer...